7,541.40

-38.67

-0.51%

51,983.98

+213.67

+0.41%

25,164.32

-272.68

-1.07%

2,805.88

-5.97

-0.21%

4.8940

-0.0350

-0.71%

21.37

+1.95

+10.04%

3,956.70

+57.80

+1.48%

76,758.89

-1,014.17

-1.30%

Crude Oil Dec 26

96.06

-8.06

-7.74%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

ABVC BioPharma, Inc. (ABVC)

0.9801 -0.0199 (-1.99%)

At close: 4:00:01 PM EST

Loading Chart for ABVC

Chart Range Bar

Interval:

In partnership with ChartIQ

/C O R R E C T I O N - WallachBeth Capital LLC/

/C O R R E C T I O N - WallachBeth Capital LLC/

ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million

ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million

ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders

ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders

ABVC BioPharma Reports 2025 Form 10-K

ABVC BioPharma Reports 2025 Form 10-K

ABVC BioPharma Provides Corporate and Structural Update

ABVC BioPharma Provides Corporate and Structural Update

ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States

ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030

ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030

ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received

ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received

ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million

ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million

ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025

ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025

Mobilize your Website

View Site in Mobile | Classic

Share by: